NRx Pharmaceuticals, Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
NRXP Nasdaq 8081 www.nrxpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - Jun 25th, 2026 2:01 pm
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - Jun 25th, 2026 5:00 am
Sector Update: Healthcare Stocks Advance Late Afternoon - Jun 24th, 2026 1:32 pm
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Jun 24th, 2026 11:18 am
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - Jun 23rd, 2026 9:05 am
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression - Jun 22nd, 2026 5:00 am
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... - Jun 17th, 2026 4:19 pm
NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share - Jun 10th, 2026 12:22 pm
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - Jun 5th, 2026 6:50 am
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option - Jun 4th, 2026 3:12 pm
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock - Jun 3rd, 2026 6:18 am
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - Jun 2nd, 2026 2:01 pm
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 - May 28th, 2026 5:00 am
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - May 27th, 2026 5:00 am
Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts - May 24th, 2026 5:49 am
NRx Pharmaceuticals Q1 Earnings Call Highlights - May 18th, 2026 7:05 am
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 18th, 2026 5:00 am
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates - May 15th, 2026 3:55 pm
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update - May 14th, 2026 5:00 am
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality - May 7th, 2026 6:00 am